NRX Pharmaceuticals, Inc.

NRX Pharmaceuticals, Inc. (Nasdaq: NRXP) is a clinical-stage biopharmaceutical company that became a public entity through its business combination with Big Rock Partners Acquisition Corp., a blank-check company sponsored by Big Rock Partners LLC that completed its initial public offering in 2019. The merger closed in 2021, bringing NRX Pharmaceuticals into the public markets under the healthcare and life sciences sector, where the company focuses on treatments for life-threatening central nervous system and critical care conditions. The 10-Q filing dated May 21, 2021 reflects one of the company's earliest quarterly disclosures as a combined public entity. For comprehensive data on NRXP, including deal timelines, filings, and sponsor history, sign up for full access at SpacDesk.